Chromosome 16 tumor-suppressor genes in breast cancer

Genes Chromosomes and Cancer

Volumn 45, Issue 6, 2006, Pages 527-535

  Rakha, Emad A ^a   Green, Andrew R ^a   Powe, Des G ^a   Roylance, Rebecca ^b   Ellis, Ian O ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE KINASE; RNA HELICASE; UBIQUITIN PROTEIN LIGASE; UVOMORULIN;

BREAST CANCER; CARCINOGENESIS; CDH1 GENE; CHROMOSOME 16; CHROMOSOME ARM; COMPARATIVE GENOMIC HYBRIDIZATION; DDX19 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE IDENTIFICATION; GENE MAPPING; GENOME; HETEROZYGOSITY LOSS; HUMAN; KARYOTYPE; KARYOTYPING; PRIORITY JOURNAL; PSKH1 GENE; REVIEW; TRADD GENE; TUMOR SUPPRESSOR GENE; WWP2 GENE;

BREAST NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; GENES, OVERLAPPING; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; NUCLEIC ACID HYBRIDIZATION;

EID: 33646591281     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20318     Document Type: Review

References (110)

1. Ascano JJ, Frierson H Jr., Moskaluk CA, Harper JC, Roviello F, Jackson CE, El-Rifai W, Vindigni C, Tosi P, Powell SM. 2001. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 14:942-949.
2. Asgeirsson KS, Jo JG, Tryggvadottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, Ogmundsdottir HM. 2000. Altered expression of E-cadherin in breast cancer, patterns, mechanisms and clinical significance. Eur J Cancer 36:1098-1106.
3. Aulmann S, Blaker H, Penzel R, Rieker RJ, Otto HF, Sinn HP. 2003. CTCF gene mutations in invasive ductal breast cancer. Breast Cancer Res Treat 80:347-352.
4. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Tajiri T, Onda M, Emi M. 2000. Identification of a 1-Mb common region at 16q24.1-24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer 28:38-44.
5. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. 1994. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845-3852.
6. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. 2000. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60:2140-2145.
7. Berx G, Becker KF, Hofler H, van Roy F. 1998. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12:226-237.
8. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. 1995. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 14:6107-6115.
9. Boldog F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Waggoner B, Lundstrom R, Jacobson J, Mullokandov MR, Klinger H, Drabkin HA. 1997. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 6:193-203.
10. Braungart E, Schumacher C, Hartmann E, Nekarda H, Becker KF, Hofler H, Atkinson MJ. 1999. Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer. J Pathol 187:530-534.
11. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. 1999a. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187:396-402.
12. Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. 1999b. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189:521-526.
13. Buerger H, Mommers EC, Littmann R, Simon R, Diallo R, Poremba C, Dockhorn-Dworniczak B, van Diest PJ, Boecker W. 2001a. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194:165-170.
14. Buerger H, Schmidt H, Beckmann A, Zanker KS, Boecker W, Brandt B. 2001b. Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis. J Clin Pathol 54:836-840.
15. Buerger H, Korsching E, Kemming D, Cleton-Jansen AM, Boecker W, Brandt B. 2005. Influence of different mechanisms of chromosome 16q-loss in invasive breast cancer on differential gene expression. Third joint meeting of the British division of IAP and the Pathological Society of Great Britain and Ireland, Newcastle, UK. Abstract 20:31.
16. Callen DF, Crawford J, Derwas C, Cleton-Jansen AM, Cornelisse CJ, Baker E. 2002. Defining regions of loss of heterozygosity of 16q in breast cancer cell lines. Cancer Genet Cytogenet 133:76-82.
17. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. 1990. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755.
18. Chen T, Sahin A, Aldaz CM. 1996. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56:5605-5609.
19. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Ried T, Kuehl WM. 1998. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463.
20. Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee R Cornelisse CJ. 1994. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer 9:101-107.
21. Cleton-Jansen AM, Moerland EW, Pronk JC, van Berkel CG, Apostolou S, Crawford J, Savoia A, Auerbach AD, Mathew CG, Callen DF, Cornelisse CJ. 1999. Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3. Br J Cancer 79:1049-1052.
22. Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, McCallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW, Smit VT, Harris WH, Millis R, Morgan NV; Barnes D, Mathew CG, Cornelisse CJ. 2001. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 61:1171-1177.
23. Cleton-Jansen AM, Buerger H, Haar N, Philippo K, van de Vijver MJ, Boecker W, Smit VT, Cornelisse CJ. 2004. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41:109-116.
24. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM. 1997. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183:404-411.
25. Devilee P, Cleton-Jansen AM, Cornelisse CJ. 2001. Ever since Knudson. Trends Genet 17:569-573.
26. Di Cristofano C, Mrad K, Zavaglia K, Bertacca G, Aretini P, Cipollini G, Bevilacqua G, Ben Romdhane K, Cavazzana A. 2005. Papillary lesions of the breast: a molecular progression? Breast Cancer Res Treat 90:71-76.
27. Dorion-Bonnet F, Mautalen S, Hostein I, Longy M. 1995. Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers. Genes Chromosomes Cancer 14:171-181.
28. Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DTH, Geurts-Moespot A, Span PN, Foekens JA, Sweep FCGJ. 2004. The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194-6202.
29. Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R. 1997. Loss of heterozygosity on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer 19:185-191.
30. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. 2002. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21:1832-1840.
31. Dutrillaux B, Gerbault-Seureau M, Zafrani B. 1990. Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet 49:203-217.
32. El Yazidi-Belkoura I, Adriaenssens E, Dolle L, Descamps S, Hondermarck H. 2003. Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells. J Biol Chem 278:16952-16956.
33. Etzell JE, Devries S, Chew K, Florendo C, Molinaro A, Ljung BM, Waldman FM. 2001. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 32:292-296.
34. Farabegoli F, Hermsen MA, Ceccarelli C, Santini D, Weiss MM, Meijer GA, van Diest PJ. 2004. Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma. Mod Pathol 17:449-455.
35. Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B. 1998. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 23:300-306.
36. Frengen E, Rocca-Serra P, Shaposhnikov S, Taine L, Thorsen J, Bepoldin C, Krekling M, Lafon D, Aas KK, El Moneim AA, Johansen H, Longy M, Prydz H, Dorion-Bonnet F. 2000. High-resolution integrated map encompassing the breast cancer loss of heterozygosity region on human chromosome 16q22.1. Genomics 70:273-285.
37. Go WY, Liu X, Roti MA, Liu F, Ho SN. 2004. NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci USA 101:10673-10678.
38. Godfrey TE, Cher ML, Chhabra V, Jensen RH. 1997. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet 98:36-42.
39. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. 2001. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 193:40-47.
40. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. 1998. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 58:2166-2169.
41. Hislop RG, Pratt N, Stocks SC, Steel CM, Sales M, Goudie D, Robertson A, Thompson AM. 2002. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 89:1581-1586.
42. Ho GH, Calvano JE, Bisogna M, Van Zee KJ. 2001. Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas. Breast Cancer Res Treat 69:115-122.
43. Horwitz M, Benson KF, Li FQ, Wolff J, Leppert MF, Hobson L, Mangelsdorf M, Yu S, Hewett D, Richards RI, Raskind WH. 1997. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. Am J Hum Genet 61:873-881.
44. Iida A, Isobe R, Yoshimoto M, Kasumi F, Nakamura Y, Emi M. 1997. Localization of a breast cancer tumour-suppressor gene to a 3-cM interval within chromosomal region 16q22. Br J Cancer 75:264-267.
45. Kashiwaba M, Tamura G, Suzuki Y, Maesawa C, Ogasawara S, Sakata K, Satodate R. 1995. Epithelial-cadherin gene is not mutated in ductal carcinomas of the breast. Jpn J Cancer Res 86:1054-1059.
46. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. 1999. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 15:715-720.
47. Knudson AG. 1996. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1223:135-140.
48. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen A-M, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G, Sutherland GR, Callen DF. 2002. CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res 62:4599-4604.
49. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM. 2003. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167-7175.
50. Korsching E, Packeisen J, Helms MW, Kersting C, Voss R, van Diest PJ, Brandt B, van der Wall E, Boecker W, Burger H. 2004. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer 90:1422-1428.
51. Kouvaraki M, Gorgoulis VG, Rassidakis GZ, Liodis P, Koutroumbi E, Markopoulos C, Gogas J, Kittas C. 2001. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors. Anticancer Res 21:991-999.
52. Kovacs A, Walker RA, Nagy A, Gomba S, Jones L, Dearing S. 2002. [Immunohistochemical study of P-cadherin in breast cancer]. Orv Hetil 143:405-409.
53. Lakhani SR, Collins N, Stratton MR, Sloane JP. 1995. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48:611-615.
54. Larsen F, Solheim J, Kristensen T, Kolsto AB, Prydz H. 1993. A tight cluster of five unrelated human genes on chromosome 16q22.1. Hum Mol Genet 2:1589-1595.
55. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. 1997. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 57:1058-1062.
56. Louvet-Vallee S, Vinot S, Maro B. 2005. Mitotic spindles and cleavage planes are oriented randomly in the two-cell mouse embryo. Curr Biol 15:464-469.
57. Loveday RL, Greenman J, Simcox DL, Speirs V, Drew PJ, Monson JR, Kerin MJ. 2000. Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 86:494-500.
58. Mady HH, Hasso S, Melhem MF. 2002. Expression of E2F-4 gene in colorectal adenocarcinoma and corresponding covering mucosa: an immunohistochemistry, image analysis, and immunoblot study. Appl Immunohistochem Mol Morphol 10:225-230.
59. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD. 1996. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 56:5484-5489.
60. Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards RI. 2000. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 60:1683-1689.
61. Mason JE, Goodfellow PJ, Grundy PE, Skinner MA. 2000. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor. J Pediatr Surg 35:891-896; discussion 896-897.
62. Maw MA, Grundy PE, Millow LJ, Eccles MR, Dunn RS, Smith PJ, Feinberg AR Law DJ, Paterson MC, Telzerow PE. 1992. A third Wilms' tumor locus on chromosome 16q. Cancer Res 52:3094-3098.
63. Medhioub M, Vaury C, Hamelin R, Thomas G. 2000. Lack of somatic mutation in the coding sequence of SIAH1 in tumors hemizygous for this candidate tumor suppressor gene. Int J Cancer 87:794-797.
64. Miller BJ, Wang D, Krahe R, Wright FA. 2003. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 73:748-767.
65. Moerland E, Breuning MH, Cornelisse CJ, Cleton-Jansen AM. 1997. Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes. Br J Cancer 76:1550-1553.
66. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. 2000. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer 88:2072-2081.
67. Moll R, Mitze M, Frixen UH, Birchmeier W. 1993. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143:1731-1742.
68. Nagai MA, Yamamoto L, Salaorni S, Pacheco MM, Brentani MM, Barbosa EM, Brentani RR, Mazoyer S, Smith SA, Ponder BA, et al. 1994. Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes Chromosomes Cancer 11:58-62.
69. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, Yamaoka Y, Ikenaga M, Imura H, Ishizaki K. 1992. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 51:862-868.
70. Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N, Waldman FM. 1997. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74:513-517.
71. O'Reilly J, Chipper L, Springall F, Herrmann R. 2000. A unique structural abnormality of chromosome 16 resulting in a CBF beta-MYH11 fusion transcript in a patient with acute myeloid leukemia, FAB M4. Cancer Genet Cytogenet 121:52-55.
72. Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ, Watson JE. 2000. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60:1690-1697.
73. Piao Z, Park C, Kim JJ, Kim H. 1999. Deletion mapping of chromosome 16q in hepatocellular carcinoma. Br J Cancer 80:850-854.
74. Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G. 2002. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 80:303-310.
75. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, Donis-Keller H. 1995. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55:3399-3405.
76. Rakha EA, Pinder SE, Paish EC, Robertson JF, Ellis IO. 2004a. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. J Pathol 203:754-761.
77. Rakha EA, Pinder SE, Paish CE, Ellis IO. 2004b. Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. Br J Cancer 91:1591-1596.
78. Rakha EA, Armour JA, Pinder SE, Paish CE, Ellis IO. 2005. High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int J Cancer 114:720-729.
79. Rodgers CS, Hill SM, Hulten MA. 1984. Cytogenetic analysis in human breast carcinoma. I. Nine cases in the diploid range investigated using direct preparations. Cancer Genet Cytogenet 13:95-119.
80. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D. 1999. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433-1436.
81. Roylance R, Gorman P, Hanby A, Tomlinson I. 2002. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32-36.
82. Roylance R, Droufakou S, Gorman P, Gillett C, Hart IR, Hanby A, Tomlinson I. 2003. The role of E-cadherin in low-grade ductal breast tumourigenesis. J Pathol 200:53-58.
83. Sato M, Mori Y, Sakurada A, Fukushige S, Ishikawa Y, Tsuchiya E, Saito Y, Nukiwa T, Fujimura S, Horii A. 1998. Identification of a 910-kb region of common allelic loss in chromosome bands 16q24.1-q24.2 in human lung cancer. Genes Chromosomes Cancer 22:1-8.
84. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y. 1990. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50:7184-7189.
85. Savino M, d'Apolito M, Centra M, van Beerendonk HM, Cleton-Jansen AM, Whitmore SA, Crawford J, Callen DF, Zelante L, Savoia A. 1999. Characterization of copine VII, a new member of the copine family, and its exclusion as a candidate in sporadic breast cancers with loss of heterozygosity at 16q24.3. Genomics 61:219-226.
86. Scheuerpflug CG, Lichter P, Debatin KM, Mincheva A. 2001. Assignment of TRADD to human chromosome band 16q22 by in situ hybridization. Cytogenet Cell Genet 92:347-348.
87. Schmitt C, von Kobbe C, Bachi A, Pante N, Rodrigues JP, Boscheron C, Rigaut G, Wilm M, Seraphin B, Carmo-Fonseca M, Izaurralde E. 1999. Dbp5, a DEAD-box protein required for mRNA export, is recruited to the cytoplasmic fibrils of nuclear pore complex via a conserved interaction with CAN/Nup159p. Embo J 18:4332-4347.
88. Schmutzler RK, Homann A, Bierhoff E, Wiestler OD, von Daimling A, Krebs D. 1995. [Detection of genetic alterations in sporadic breast tumors]. Gynakol Geburtshilfliche Rundsch 35 Suppl 1:63-67.
89. Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Becker I, Atkinson M, Gessler M, Hofler H. 2000. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours. J Pathol 191:162-169.
90. Shelley Hwang E, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM. 2004. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 100:2562-2572.
91. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW. 2000. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60:3884-3892.
92. Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, Pinkel D, van Diest PJ, Verheijen RH, Albertson DG. 2003. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 22:4281-4286.
93. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong J-T. 2005. Frequent somatic mutations of the transcription factor ATBFl in human prostate cancer. Nat Genet 37:407-412.
94. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J. 1996. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 17:225-233.
95. Taine L, Rocca-Serra P, El Moneim AA, Verdier N, Moradkhani K, Saura R, Gorry P, Longy M, Bonnet F. 2003. The common fragile site FRA16C does not map within the 16q smallest region of overlap number 2 frequently lost in breast carcinoma. Cancer Genet Cytogenet 144:85-86.
96. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. 1998. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177-184.
97. Tomlinson IP, Lambros MB, Roylance RR. 2002. Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer 34:349-353.
98. Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S. 1994. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res 54:513-517.
99. Tsuda H, Takarabe T, Hirohashi S. 1999. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer 84:381-387.
100. van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ, Cleton-Jansen AM. 2005. Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7:R998-R1004.
101. Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voute PA, Baas F. 1997. Allelotype of pediatric rhabdomyosarcoma. Oncogene 15:1309-1314.
102. Vos CB, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen AM, Cornelisse CJ, van de Vijver MJ. 1999. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 81:1410-1418.
103. Waldman FM, Hwang ES, Etzell J, Eng C, DeVries S, Bennington J, Thor A. 2001. Genomic alterations in tubular breast carcinomas. Hum Pathol 32:222-226.
104. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. 2004. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64-71.
105. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T, Aburatani H. 2003. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63:8629-8633.
106. Whitmore SA, Crawford J, Apostolou S, Eyre H, Baker E, Lower KM, Settasatian C, Goldup S, Seshadri R, Gibson RA, Mathew CG, Cleton-Jansen A-M, Savoia A, Pronk JC, Auerbach AD, Doggett NA, Sutherland GR, Callen DF. 1998a. Construction of a high-resolution physical and transcription map of chromosome 16q24.3: a region of frequent loss of heterozygosity in sporadic breast cancer. Genomics 50:1-8.
107. Whitmore SA, Settasatian C, Crawford J, Lower KM, McCallum B, Seshadri R, Cornelisse CJ, Moerland EW, Cleton-Jansen AM, Tipping AJ, Mathew CG, Savnio M, Savoia A, Verlander P, Auerbach AD, Van Berkel C, Pronk JC, Doggett NA, Callen DF. 1998b. Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer. Genomics 52:325-331.
108. Wong JC, Gokgoz N, Alon N, Andrulis IL, Buchwald M. 2003. Cloning and mutation analysis of ZFP276 as a candidate tumor suppressor in breast cancer. J Hum Genet 48:668-671.
109. Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM, Jin Y. 2004. Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem 279:23495-23503.
110. Zhao L, Hayes K, Van Fleet T, Glassman A. 2003. Detection of a novel reciprocal t(16;22)(q11.2;q12) in a Ewing sarcoma. Cancer Genet Cytogenet 140:55-57.